ADVANCED/METASTATIC SOLID TUMORS
Clinical trials for ADVANCED/METASTATIC SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new ADVANCED/METASTATIC SOLID TUMORS trials appear
Sign up with your email to follow new studies for ADVANCED/METASTATIC SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat tumors: targeted drug HRS-6719 enters human trials
Disease control Recruiting nowThis study tests a new drug called HRS-6719 in people with advanced solid tumors that lack a gene called MTAP. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 120 participants will take part across multiple centers.
Matched conditions: ADVANCED/METASTATIC SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New cancer drug HLX316 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…
Matched conditions: ADVANCED/METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug ATG-022 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…
Matched conditions: ADVANCED/METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New cancer drug DB-1317 enters first human tests
Disease control Recruiting nowThis early-phase trial is testing a new drug called DB-1317 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and then expanding to see if the drug shows any signs of shrinking tumors. About 2…
Matched conditions: ADVANCED/METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New smart drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…
Matched conditions: ADVANCED/METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New Two-in-One cancer drug enters human testing
Disease control Recruiting nowThis early-phase study tests HLX37, a new drug that targets two cancer growth pathways (PD-L1 and VEGF) at once, in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Up to 254 par…
Matched conditions: ADVANCED/METASTATIC SOLID TUMORS
Phase: EARLY_PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New targeted drug SYS6043 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called SYS6043 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The trial will first find the safest dose, then expand to…
Matched conditions: ADVANCED/METASTATIC SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug duo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called ADG126 combined with pembrolizumab (a standard immunotherapy) in people with advanced or metastatic solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About…
Matched conditions: ADVANCED/METASTATIC SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC